Company Profile For Elan Corp PLC

Elan Corp PLC (ELN.L) (London Stock Exchange)

sector: Healthcare · industry: Pharmaceuticals - Generic & Specialty ·

As of 7 Aug 2009

5.41EUR

Price Change

+0.00

Percent Change

+0.00%

Analyst Recommendations

Overview

Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan’s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain. EDT focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing. In September 2009, the Company and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP).

Quick Financial Synopsis

BRIEF: For the six months ended 30 June 2009, Elan Corporation, plc's revenues increased 9% to $384.6M. Net loss increased 4% to $165.3M. Revenues reflect an increase in income from Biopharmaceuticals segment. Net loss reflects an increase in cost of sales, higher research & development expense, a decrease in interest income and lower gross profit margin. the Group develops drugs and drug delivery system.